Stay updated on Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial
Sign up to get notified when there's something new on the Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial page.

Latest updates to the Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial page
- CheckyesterdayChange DetectedThe study record shows new timestamps reflecting recent maintenance: last update posted on 2026-07-08 and last update submitted on 2026-06-12, along with a June 2026 entry. This indicates routine record upkeep rather than changes to the study details.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision tag updated from v3.6.0 to v3.6.3 to reflect a newer page build. This change does not alter visible content, study details, or user-facing features.SummaryDifference0.0%

- Check30 days agoChange DetectedAdded a recruitment status note indicating enrollment is closed. Added/standardized navigation and help-content sections (How to Read a Study Record, Common Questions, How to Join a Study, Intervention/Treatment) and removed the older 'Intervention / Treatment' label to align with a site-wide formatting update.SummaryDifference0.4%

- Check37 days agoChange DetectedThe site now shows Revision: v3.5.5, replacing the previous Revision: v3.5.4. This indicates a recent software update to the platform and does not alter the study details or page content.SummaryDifference0.0%

- Check59 days agoChange DetectedThe page's revision is updated from v3.5.3 to v3.5.4, indicating a new version of the page. This typically reflects minor edits or metadata adjustments in the page history.SummaryDifference0.0%

- Check80 days agoChange DetectedClinicalTrials.gov’s page footer revision label was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

Stay in the know with updates to Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Her2 Therapy & Pembrolizumab in Neoadjuvant Clinical Trial page.